View Older Stories View More Recent Stories
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P Lazard Active ETF Trust For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P LAZARD GLOBAL TOTAL RETU For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P Lazard Active ETF Trust For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P LAZARD FUNDS INC For: Dec 31
-
Form NPORT-P Lazard Active ETF Trust For: Dec 31
-
Blackboard, Formerly Anthology, Emerges Debt-Free and Focused on Enabling Transformational Teaching and Learning
-
Form N-CSR LAZARD FUNDS INC For: Dec 31
-
Form N-CSR Lazard Active ETF Trust For: Dec 31
-
Form N-CSR LAZARD GLOBAL TOTAL RETU For: Dec 31
-
Form D/A LAZARD GLOBAL LISTED
-
1847 Holdings Subsidiary CMD Secures Over $4 Million in New Contracts, Expanding Pipeline to $17.4 Million in Anticipated Q1–Q2 Project Awards
-
Form X-17A-5 LAZARD FRERES & CO. LLC For: Dec 31
-
Form X-17A-5 LAZARD ASSET MANAGEMENT For: Dec 31
-
Form APP ORDR Lazard Active ETF Trust
-
Form APP NTC Lazard Active ETF Trust
-
Marsh adds Peter Harrison to board of directors
-
Marsh Appoints Peter Harrison to Its Board of Directors
-
Form D/A Lazard Japanese Strategi
-
Arcline Investment Management to Acquire Hydraulics International, Inc.
-
Form N-CSR LAZARD RETIREMENT SERIES For: Dec 31
-
Form 4 Lazard, Inc. For: Feb 20 Filed by: Farr Tracy
-
Form 4 Lazard, Inc. For: Feb 20 Filed by: Hogbin Christopher
-
Form 4 Lazard, Inc. For: Feb 20 Filed by: Soto Alexandra
-
Form 4 Lazard, Inc. For: Feb 20 Filed by: Gathy Michael
-
Lazard Global Total Return and Income Fund Declares Monthly Distribution and Issues Estimated Sources of the Distribution Announced in January
-
Astellas partners with Vir Biotechnology on prostate cancer treatment
-
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
-
Form 10-K Lazard, Inc. For: Dec 31
-
Form 497K LAZARD RETIREMENT SERIES
-
Form 497 LAZARD RETIREMENT SERIES
-
Form D/A Lazard ESC US Short Dura
-
Form D/A Lazard ESC US Equity
-
Form D/A Lazard ESC International
-
Form D/A Lazard ESC Global Listed
-
Form D/A Lazard ESC Global Equity
-
Form D/A Lazard ESC Emerging Mark
-
Form D/A Lazard Core Fixed Income
-
Form 4 Lazard, Inc. For: Feb 17 Filed by: Howe Stephen R. Jr.
-
Form 4 Lazard, Inc. For: Feb 17 Filed by: Alper Andrew M

